循环miRNA在多囊卵巢综合征二甲双胍作用机制及疗效预测中的作用
本研究纳入146例慢性无排卵的多囊卵巢综合征(PCOS)患者和20例非PCOS对照,所有PCOS患者接受二甲双胍治疗6个月。研究发现,恢复排卵组(MET-OV)基线miR-27a、miR-93和miR-222表达显著高于未恢复排卵组(MET-AO)和对照组,且治疗后胰岛素、黄体生成素及6种循环miRNA水平显著下降,而未恢复排卵组无变化。基于miRNA水平和临床参数构建的预测模型曲线下面积为0.807。
要点
- MET-OV组基线miR-27a、miR-93和miR-222表达显著高于MET-AO组和对照组。
- 二甲双胍治疗6个月后,MET-OV组胰岛素、黄体生成素及6种循环miRNA水平显著下降,MET-AO组无变化。
- 基于miRNA和临床参数的预测模型曲线下面积、敏感性和特异性分别为0.807、0.892和0.632。
核心结论
- 本研究表明MET-OV和MET-AO组在几种循环miRNA的基线表达和随时间变化上存在不同模式,提示异常过表达的致糖尿病miRNA参与PCOS慢性无排卵的病理生理,其下调可能有助于二甲双胍的治疗效果。
研究设计与样本
- 病例对照和前瞻性验证队列研究,在三甲大学医院开展,纳入146例慢性无排卵的PCOS患者和20例非PCOS对照。
- 所有PCOS患者接受二甲双胍治疗6个月,根据治疗后是否恢复排卵分为MET-OV组和MET-AO组。
主要发现
- MET-OV组与MET-AO组基线激素和代谢特征无显著差异。
- MET-OV组基线miR-27a、miR-93和miR-222表达显著高于MET-AO组和对照组。
- 二甲双胍治疗6个月后,MET-OV组胰岛素、黄体生成素、6种循环miRNA(miR-21、27a、93、221、222和223)及胰岛素抵抗稳态模型评估显著下降,MET-AO组无变化。
- 基于miRNA水平和临床参数经逻辑回归分析调整的预测模型,预测二甲双胍治疗后排卵反应的曲线下面积、敏感性和特异性分别为0.807、0.892和0.632。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the involvement of microribonucleic acids (miRNAs) in the pathogenesis of chronic anovulation and mechanism of metformin treatment in polycystic ovary syndrome (PCOS). DESIGN: Case-control and prospective validation cohort study. SETTING: Tertiary university hospital. PATIENT(S): A total of 146 patients with PCOS and chronic anovulation and 20 non-PCOS controls were enrolled. Patients who resumed ovulation after metformin treatment (MET-OV) and remained anovulatory after metformin treatment (MET-AO) were assigned to MET-OV and MET-AO groups, respectively. INTERVENTION(S): All patients with PCOS received metformin treatment for 6 months. MAIN OUTCOME MEASURE(S): Baseline and chronological changes in the plasma levels of 14 miRNAs (miR-21, 93, 132, 193b, 221, 222, 223, 27a, 125b, 200b, 212, 320a, 429, and 483) selected by literature review, anthropometric data, and hormonal as well as metabolic profiles were measured. Predictive modeling based on baseline circulatory miRNA levels and clinical parameters was performed to predict ovulation recovery after metformin treatment. RESULT(S): No significant differences were observed in the baseline hormonal and metabolic profiles between the MET-OV and MET-AO groups. However, the expression of miR-27a, miR-93, and miR-222 was significantly higher in the MET-OV group than that for the MET-AO and control groups. After 6 months of metformin treatment, the levels of insulin, luteinizing hormone, and 6 circulating miRNAs (miR-21, 27a, 93, 221, 222, and 223) and homeostatic model assessment for insulin resistance decreased significantly in the MET-OV group, but remained unchanged in the MET-AO group. The area under curve, sensitivity, and specificity of the adjusted prediction model, based on miRNA levels and clinical parameters using logistic regression analysis for predicting ovulatory response after metformin treatment, were 0.807, 0.892, and 0.632, respectively. CONCLUSION(S): The present study demonstrated a distinct pattern of baseline expression and chronological changes in the levels of several circulatory miRNAs between the MET-OV and MET-AO groups, suggesting that aberrantly overexpressed diabetogenic miRNAs are involved in the pathophysiology of chronic anovulation in PCOS, and their down-regulation might contribute toward the therapeutic effects of metformin. This could provide new insights into the mechanism of action and applicability of individualized metformin therapy in women with PCOS.
引用
- Huang CC, Yang PK, Huang YS, et al. The role of circulating miRNAs in mechanism of action and prediction of therapeutic responses of metformin in polycystic ovarian syndrome. Fertil Steril. 2023. PMID: 36627014. doi:10.1016/j.fertnstert.2022.12.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。